Biography

Ms. Chhabra Karson has served as a director since January 2023. Ms. Chhabra Karson is currently the CEO of Evercrisp Biosciences, a privately held biotechnology company, a role she has held since September 2024. Ms. Chhabra Karson has served as Executive Chair of the board of directors of Samsara Therapeutics since July 2023 and previously served as chair of the board of directors of Apexigen from July 2022 until Apexigen’s acquisition by Pyxis Oncology in August 2023. She previously served as President and Chief Executive Officer of Proteostasis Therapeutics from May 2014 until December 2020, and has served as a director on a number of private biotech boards since January 2021. From 2007 to 2014, Ms. Chhabra Karson was President and Chief Executive Officer at Allozyne, Inc. Prior to her time at Allozyne, she served as the Chief Business Officer at BioXell SpA and has also held roles of increasing responsibility at Novartis, Warner-Lambert Company, LLC, and Bristol-Myers Squibb. Ms. Chhabra Karson obtained her M.B.A. from York University and her B.Sc. from the University of Toronto. The Board believes that Ms. Chhabra Karson’s more than 20 years of operational leadership in biopharmaceutical companies and financial expertise qualify her to serve as a member of our Board.